NTBL Notable Labs Ltd Final Profit

The biotechnology platform Notable Labs, Ltd. (NTBL) demonstrates macro resilience, as the fight against oncology is not subject to seasonality. The company's financial performance history on this GURU.Markets chart shows that 0.00 determines the current value of the indicator. Personalized blood cancer therapy selection minimizes risks, while attracting AI experts through stock options ensures the staffing stability of the laboratories.

NTBL (Notable Labs, Ltd.) Net Profit history from 02/21/2024 to 11/02/2024

Analytical breakdowns and data insights for company Notable Labs (NTBL)

- stock value and consensus price forecast:
Market Price Notable Labs Corp|NTBL - Price Target Chart
- market capitalization data:
Market Value Notable Labs Corp|NTBL - Real Price to Acquire Entire Company
- business book valuation details:
Accounting Value of a Share Notable Labs|NTBL - Book Capitalization|Market Cap to Net Assets Ratio notablelabs.com|NTBL - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital Notable Labs, Ltd.|NTBL - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Notable Labs Ltd|NTBL - Company Aggregate Debts|Debts to Book Value Notable Labs Corp|NTBL - Company Long-Term Debt|Company Short-Term Indebtedness Notable Labs|Immediate Liquidity notablelabs.com
- net income and valuation multiples indicators:
NTBL - Net Income
Fundamental valuation:NTBL Notable Labs Corp

Profit reflects the final financial result after deducting all operating and tax expenses, allowing the investor to assess the actual efficiency of cash flow generation. Analyzing the net economic effect of Notable Labs, Ltd. (NTBL) on the GURU.Markets platform, one can observe how geopolitical fragmentation and reagent supply disruptions for Notable Labs, Ltd. (NTBL) limit the scaling of clinical trials, directly impacting the business's bottom-line profitability.

Main competitors

Company Net Income BeiGene Oncology (ONC)|Company Net Income Halozyme Therapeutics|RVMD: Final Profit|Net Income AAPG (Ascentage Pharma)|CGON (CG Oncology Inc) - Final Profit|Net Profit URGN (UroGen)|BCAX - Net Income|PSNL: Net Income|ERAS - Net Profit|Delcath Systems (DCTH) - Company Net Income|Y-mAbs Therapeutics Inc - Final Profit|AURA (Aura Bio) - Net Profit|Company Net Income Candel CADL|Company Net Income Accuray Incorporated (ARAY)|sellaslifesciences.com - Company Profit|Company Net Income Actuate Therapeutics ACTU|Citius Oncology Inc. (CTOR) - Company Net Income|HURA: Net Income|Protara Tx - Profit After Payment of Taxes|FATE: Net Profit|Aadi Bioscience (WHWK) - Net Profit|TCRX (TScan Therapeutics Inc) - Net Profit|Company Net Income CSBR|Company Net Income XBiotech Inc. (XBIT)|Company Net Income CVM (cel-sci.com)|Net Profit OSTX (OS Therapies Incorporated)|Radiopharm Theranostics Ltd (RADX) - Company Net Income|ARTV: Net Income|Final Profit ANL (Adlai Nortye Ltd.)|Veru Pharma (VERU) - Company Net Income|TPST (Tempest Therapeutics Corp) - Company Net Income|XLO (Xilio Therapeutics Inc) - Net Profit|Net Profit Enochian BioSciences|Net Profit MURA|Company Net Income KAPA (kairospharma.com)|Company Net Income OnKure Therapeutics OKUR|Net Financial Result CytoMed Therapeutics Ltd (GDTC)|CRIS: Net Income|Final Profit APLM (Apollomics, Inc.)|Tharimmune (THAR) - Company Net Income|ADVB (Advanced Biomed) - Company Net Income|Net Income GNPX|CLDI (Calidi Bio) - Profit After Payment of Taxes|Net Profit SBFM|xeneticbio.com - Company Profit|Salarius Pharmaceuticals, Inc. - Net Income|Net Financial Result Purple Biotech Ltd (PPBT)|AONC - Company Net Income|BGNE (BeiGene Ltd) - Company Profit|CKPT (Checkpoint Therapeutics) - Net Income|ELEV: Profit After Payment of Taxes|ICAD (iCAD Inc.) - Net Profit|Company Net Income IKNA|Company Net Income Viracta Therapeutics (VIRX)|Company Net Income MOR (MorphoSys Corporation)|Net Profit NAYA (NAYA Biosciences)|AAPGV - Net Income